4.4 Article

Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study

Journal

INTERNAL AND EMERGENCY MEDICINE
Volume 9, Issue 5, Pages 537-546

Publisher

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s11739-013-0977-z

Keywords

Smoking cessation; Smoking reduction; Quit rate; Adverse events; Electronic cigarettes; Electronic nicotine delivery devices; Cigarette substitutes

Funding

  1. Arbi Group Srl (Milano, Italy)

Ask authors/readers for more resources

Electronic cigarettes (e-Cigarette) are battery-operated devices designed to vaporise nicotine that may aid smokers to quit or reduce their cigarette consumption. Research on e-Cigarettes is urgently needed to ensure that the decisions of regulators, healthcare providers and consumers are evidence based. Here we assessed long-term effectiveness and tolerability of e-Cigarette used in a 'naturalistic' setting. This prospective observational study evaluated smoking reduction/abstinence in smokers not intending to quit using an e-Cigarette ('Categoria'; Arbi Group, Italy). After an intervention phase of 6 months, during which e-Cigarette use was provided on a regular basis, cigarettes per day (cig/day) and exhaled carbon monoxide (eCO) levels were followed up in an observation phase at 18 and 24 months. Efficacy measures included: (a) a parts per thousand yen50 % reduction in the number of cig/day from baseline, defined as self-reported reduction in the number of cig/day (a parts per thousand yen50 %) compared to baseline; (b) a parts per thousand yen80 % reduction in the number of cig/day from baseline, defined as self-reported reduction in the number of cig/day (a parts per thousand yen80 %) compared to baseline; (c) abstinence from smoking, defined as complete self-reported abstinence from tobacco smoking (together with an eCO concentration of a parts per thousand currency sign10 ppm). Smoking reduction and abstinence rates were computed, and adverse events reviewed. Of the 40 subjects, 17 were lost to follow-up at 24 months. A > 50 % reduction in the number of cig/day at 24 months was shown in 11/40 (27.5 %) participants with a median of 24 cig/day use at baseline decreasing significantly to 4 cig/day (p = 0.003). Smoking abstinence was reported in 5/40 (12.5 %) participants while combined > 50 % reduction and smoking abstinence was observed in 16/40 (40 %) participants at 24 months. Five subjects stopped e-Cigarette use (and stayed quit), three relapsed back to tobacco smoking and four upgraded to more performing products by 24 months. Only some mouth irritation, throat irritation, and dry cough were reported. Withdrawal symptoms were uncommon. Long-term e-Cigarette use can substantially decrease cigarette consumption in smokers not willing to quit and is well tolerated. (http://ClinicalTrials.govnumberNCT01195597).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Allergy

Stratification of asthma phenotypes by airway proteomic signatures

James P. R. Schofield, Dominic Burg, Ben Nicholas, Fabio Strazzeri, Joost Brandsma, Doroteya Staykova, Caterina Folisi, Aruna T. Bansal, Yang Xian, Yike Guo, Anthony Rowe, Julie Corfield, Susan Wilson, Jonathan Ward, Rene Lutter, Dominick E. Shaw, Per S. Bakke, Massimo Caruso, Sven-Erik Dahlen, Stephen J. Fowler, Ildiko Horvath, Peter Howarth, Norbert Krug, Paolo Montuschi, Marek Sanak, Thomas Sandstrom, Kai Sun, Ioannis Pandis, John Riley, Charles Auffray, Bertrand De Meulder, Diane Lefaudeux, Ana R. Sousa, Ian M. Adcock, Kian Fan Chung, Peter J. Sterk, Paul J. Skipp, Ratko Djukanovic, H. Ahmed, D. Allen, P. Badorrek, S. Ballereau, F. Baribaud, M. K. Batuwitage, A. Bedding, A. F. Behndig, A. Berglind, A. Berton, J. Bigler, M. J. Boedigheimer, K. Bonnelykke, P. Brinkman, A. Bush, D. Campagna, C. Casaulta, A. Chaiboonchoe, T. Davison, B. De Meulder, I. Delin, P. Dennison, P. Dodson, L. El Hadjam, D. Erzen, C. Faulenbach, K. Fichtner, N. Fitch, E. Formaggio, M. Gahlemann, G. Galffy, D. Garissi, T. Garret, J. Gent, E. Guillmant-Farry, E. Henriksson, U. Hoda, J. M. Hohlfeld, X. Hu, A. James, K. Johnson, N. Jullian, G. Kerry, M. Klueglich, R. Knowles, J. R. Konradsen, K. Kretsos, L. Krueger, A. -S. Lantz, C. Larminie, P. Latzin, D. Lefaudeux, N. Lemonnier, L. A. Lowe, R. Lutter, A. Manta, A. Mazein, L. McEvoy, A. Menzies-Gow, N. Mores, C. S. Murray, K. Nething, U. Nihlen, R. Niven, B. Nordlund, S. Nsubuga, J. Pellet, C. Pison, G. Pratico, M. Puig Valls, K. Riemann, J. P. Rocha, C. Rossios, G. Santini, M. Saqi, S. Scott, N. Sehgal, A. Selby, P. Soderman, A. Sogbesan, F. Spycher, S. Stephan, J. Stokholm, M. Sunther, M. Szentkereszty, L. Tamasi, K. Tariq, S. Valente, W. M. van Aalderen, C. M. van Drunen, J. Van Eyll, A. Vyas, W. Yu, W. Zetterquist, Z. Zolkipli, A. H. Zwinderman, Nora Adriaens, Antonios Aliprantis, Kjell Alving, Per Bakke, David Balgoma, Clair Barber, Frederic Baribaud, Stewart Bates, An Bautmans, Jorge Beleta, Grazyna Bochenek, Joost Brandsma, Armin Braun, Dominic Burg, Leon Carayannopoulos, Joao Pedro Carvalho da Purificacao Rocha, Romanas Chaleckis, Arnaldo D'Amico, Jorge De Alba, Inge De Lepeleire, Tamara Dekker, Annemiek Dijkhuis, Aleksandra Draper, Jessica Edwards, Rosalia Emma, Magnus Ericsson, Breda Flood, Hector Gallart, Cristina Gomez, Kerry Gove, Neil Gozzard, John Haughney, Lorraine Hewitt, Jens Hohlfeld, Cecile Holweg, Richard Hu, Sile Hu, Juliette Kamphuis, Erika J. Kennington, Dyson Kerry, Hugo Knobel, Johan Kolmert, Maxim Kots, Scott Kuo, Maciej Kupczyk, Bart Lambrecht, Saeeda Lone-Latif, Matthew J. Loza, Lisa Marouzet, Jane Martin, Sarah Masefield, Caroline Mathon, Sally Meah, Andrea Meiser, Leanne Metcalf, Maria Mikus, Montse Miralpeix, Philip Monk, Shama Naz, Ben Nicholas, Peter Nilsson, Jorgen Ostling, Antonio Pacino, Susanna Palkonen, Stelios Pavlidis, Giorgio Pennazza, Anne Petren, Sandy Pink, Anthony Postle, Pippa Powell, Malayka Rahman-Amin, Navin Rao, Lara Ravanetti, Emma Ray, Stacey Reinke, Leanne Reynolds, John Riley, Martine Robberechts, Amanda Roberts, Kirsty Russell, Michael Rutgers, Marco Santoninco, Corinna Schoelch, James P. R. Schofield, Marcus Sjodin, Paul J. Skipp, Barbara Smids, Caroline Smith, Jessica Smith, Katherine M. Smith, Doroteya Staykova, Kai Sun, John-Olof Thorngren, Bob Thornton, Jonathan Thorsen, Marianne van de Pol, Marleen van Geest, Jenny Versnel, Anton Vink, Frans Wald, Samantha Walker, Jonathan Ward, Zsoka Weiszhart, Kristiane Wetzel, Craig E. Wheelock, Coen Wiegman, Sian Williams, Susan J. Wilson, Ashley Woodcock, Xian Yang, Elizabeth Yeyasingham, Jan-Bas Prins, Martina Gahlemann, Luigi Visintin, Hazel Evans, Martine Puhl, Lina Buzermaniene, Val Hudson, Laura Bond, Pim de Boer, Guy Widdershoven, Ralf Sigmund, Amanda Roberts, David Supple, Dominique Hamerlijnck, Jenny Negus, Julitte Kamphuis, Lehanne Sergison, Luigi Visintin, Pim de Boer, Susanne Onstein, William MacNee, Renato Bernardini, Louis Bont, Per-Ake Wecksell, Pim de Boer, Martina Gahlemann, Ralf Sigmund

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Article Medicine, General & Internal

A double blind randomized controlled trial investigating efficacy and safety of varenicline for smoking cessation in patients with type 2 diabetes: study protocol

C. Russo, P. Caponnetto, F. Cibella, M. Maglia, A. Alamo, D. Campagna, L. Frittitta, M. Di Mauro, C. Leotta, E. Mondati, A. Krysinski, E. Franek, R. Polosa

Summary: Reducing exposure to cigarette smoke is crucial for public health and diabetic patients. While smoking cessation is challenging for diabetic patients, a clinical trial testing the efficacy and safety of varenicline in smokers with type 2 diabetes could provide valuable insights and potentially improve success rates of quitting smoking for this population.

INTERNAL AND EMERGENCY MEDICINE (2021)

Article Medicine, General & Internal

International randomised controlled trial evaluating metabolic syndrome in type 2 diabetic cigarette smokers following switching to combustion-free nicotine delivery systems: the DIASMOKE protocol

Arkadiusz Krysinski, Cristina Russo, Sarah John, Jonathan D. Belsey, Davide Campagna, Pasquale Caponnetto, Lorina Vudu, Chong Wei Lim, Francesco Purrello, Maurizio Di Mauro, Farrukh Iqbal, David Fluck, Edward Franek, Riccardo Polosa, Pankaj Sharma

Summary: This study aims to investigate the long-term impact of using C-F NDS on type 2 diabetic smokers, testing the hypothesis that switching from conventional cigarettes to C-F NDS can lead to measurable improvements in MetS factors over a 2-year period.

BMJ OPEN (2021)

Review Medicine, General & Internal

Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research

Cother Hajat, Emma Stein, Arielle Selya, Riccardo Polosa

Summary: This article examines published vaping studies in medical journals and identifies serious flaws in study design and methodology. Many studies lack a clear hypothesis statement and fail to address the research question effectively. The identification of outcome measures and control of confounding factors are also insufficient. As a result, the conclusions and assertions made in these studies are unreliable. The article calls for future researchers to adhere to scientific methods to produce more reliable findings and conclusions in vaping research.

INTERNAL AND EMERGENCY MEDICINE (2022)

Letter Critical Care Medicine

Taking for Granted Conclusions from Studies that Cannot Prove Causality of Respiratory Symptoms and Vaping

Davide Campagna, Grazia Caci

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Editorial Material Medicine, General & Internal

COVID-19 and emergency departments: need for a validated severity illness score. The history of emerging CovHos score

Davide Campagna, Grazia Caci, Elisa Trovato, Giuseppe Carpinteri, Lucia Spicuzza

INTERNAL AND EMERGENCY MEDICINE (2022)

Correction Medicine, General & Internal

Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research (vol 17, pg 887, 2022)

Cother Hajat, Emma Stein, Arielle Selya, Riccardo Polosa

INTERNAL AND EMERGENCY MEDICINE (2022)

Article Medicine, General & Internal

Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes A Randomized Clinical Trial

Cristina Russo, Magdalena Walicka, Pasquale Caponnetto, Fabio Cibella, Marilena Maglia, Angela Alamo, Davide Campagna, Lucia Frittitta, Maurizio Di Mauro, Grazia Caci, Arkadiusz Krysinski, Edward Franek, Riccardo Polosa

Summary: This study aimed to evaluate the efficacy and safety of varenicline in helping patients with type 2 diabetes quit smoking. The results showed that the inclusion of varenicline in a smoking cessation program was effective in achieving long-term abstinence without serious adverse events. Varenicline should be routinely used to help patients with type 2 diabetes stop smoking.

JAMA NETWORK OPEN (2022)

Editorial Material Medicine, General & Internal

Different death rates between COVID-19 waves among unvaccinated patients: moving beyond lessons learned

Davide Campagna, Crsitina Russo, Elisa Trovato, Joseph Bridgeman, Riccardo Polosa

INTERNAL AND EMERGENCY MEDICINE (2023)

Review Biochemistry & Molecular Biology

The Impact of Tobacco Cigarettes, Vaping Products and Tobacco Heating Products on Oxidative Stress

Rosalia Emma, Massimo Caruso, Davide Campagna, Roberta Pulvirenti, Giovanni Li Volti

Summary: Cells constantly produce oxidizing species through their metabolic activity, which is countered by the production of antioxidant species. Smoking is a major exogenous source of these species. Next-generation products like electronic cigarettes and tobacco heating products are proposed as alternatives to reduce the harmful effects of smoking. Tobacco smoke has been established to have significant impact on oxidative stress signaling, while further research is needed to understand the long-term oxidative effects of these alternative products.

ANTIOXIDANTS (2022)

Review Respiratory System

Health impact of e-cigarettes and heated tobacco products in chronic obstructive pulmonary disease: current and emerging evidence

Jaymin B. Morjaria, Davide Campagna, Grazia Caci, Renee O'Leary, Riccardo Polosa

Summary: Quitting smoking is the only proven method to slow down the progression of COPD. However, many COPD smokers do not respond to smoking cessation interventions and may benefit from using non-combustible nicotine delivery alternative such as heated tobacco products (HTPs) and e-cigarettes (ECs) to reduce harm from cigarette smoke.

EXPERT REVIEW OF RESPIRATORY MEDICINE (2023)

Article Public, Environmental & Occupational Health

Smoking habits predict adverse effects after mRNA COVID-19 vaccine: Empirical evidence from a pilot study

D. Ponticelli, L. Losa, D. Campagna, R. Magliuolo, A. Vitale, D. Cacciapuoti, A. Zampella, L. Alleanza, B. Schiavone, L. Spicuzza, P. Ferrara

Summary: This research aimed to investigate the possible association between smoking habits and the incidence of adverse effects (AEs) after mRNA COVID-19 vaccine. A sample of Italian healthcare workers was longitudinally observed, and the occurrence of AEs after vaccination was evaluated. The study found a correlation between smoking habits and some adverse reactions after COVID-19 vaccination.

PUBLIC HEALTH (2023)

Article Public, Environmental & Occupational Health

Comparing the Effectiveness, Tolerability, and Acceptability of Heated Tobacco Products and Refillable Electronic Cigarettes for Cigarette Substitution (CEASEFIRE): Randomized Controlled Trial

Pasquale Caponnetto, Davide Campagna, Marilena Maglia, Francesca Benfatto, Rosalia Emma, Massimo Caruso, Grazia Caci, Barbara Busa, Alfio Pennisi, Maurizio Ceracchi, Marcello Migliore, Maria Signorelli

Summary: This study compared the effectiveness of heated tobacco products (HTPs) and electronic cigarettes (ECs) for smokers who do not intend to quit. The results showed that both HTPs and ECs can effectively reduce cigarette consumption, and the user experience and risk perception are similar between the two.

JMIR PUBLIC HEALTH AND SURVEILLANCE (2023)

Review Microbiology

An update on lateral flow immunoassay for the rapid detection of SARS- CoV-2 antibodies

Lucia Spicuzza, Davide Campagna, Chiara Di Maria, Enrico Sciacca, Salvatore Mancuso, Carlo Vancheri, Gianluca Sambataro

Summary: In the past three years since the COVID-19 pandemic outbreak, there has been an unprecedented development of novel diagnostic tests. The lateral flow immunoassay (LFIA) has been widely studied as a point-of-care (POC) test to detect SARS-CoV-2 antibodies. LFIAs are faster, cheaper, and more user-friendly compared to laboratory tests, making them accessible in areas with limited resources. The accuracy and utility of LFIAs have been evaluated, and they have been used for seroprevalence surveillance and to assess immunization in the vaccinated population.

AIMS MICROBIOLOGY (2023)

Article Substance Abuse

Critical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electronic cigarettes

Renee O'Leary, Riccardo Polosa, Giovanni Li Volti

Summary: In preparation for the 2021 revision of the European Union Tobacco Products Directive, the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) has published a Preliminary Opinion on Electronic Cigarettes, but their conclusions lack adequate scientific evidence and fail to discuss the potential health benefits of using combustion-free nicotine-containing products as substitutes for tobacco cigarettes.

HARM REDUCTION JOURNAL (2021)

No Data Available